RVP RETRACTABLE TECHNOLOGIES INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 946563 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY5.3%
TTM EPS YoY4.5%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—
Margins
Gross margin-5.2%
Operating margin-61.1%
Net margin-16.1%
FCF margin—
EBITDA margin-40.4%
Returns
ROE-8.3%
ROA-4.3%
ROIC (approx.)-25.6%
Asset turnover0.27x
Leverage & solvency
Liabilities / assets49.2%
Debt / equity0.00x
Current ratio4.54x
Interest coverage-299.43x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-1.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $38.27M | $33.05M |
| Cost of revenue | $38.22M | $34.08M |
| Gross profit | $47,046 | -$1.03M |
| R&D expense | $675,567 | $673,944 |
| SG&A expense | $12.77M | $13.56M |
| Operating income | -$21.18M | -$21.11M |
| Interest expense | $87,904 | $122,500 |
| Pretax income | -$12.27M | -$3.52M |
| Income tax | $291,293 | $8.37M |
| Net income | -$12.57M | -$11.89M |
| EBITDA | -$13.41M | -$13.54M |
| EPS (basic) | -0.43 | -0.40 |
| EPS (diluted) | -0.43 | -0.40 |
| Weighted avg. shares (diluted) | 29.94M | 29.94M |
| Balance sheet | ||
| Cash & equivalents | $2.59M | $4.24M |
| Receivables | $7.90M | $7.79M |
| Inventory | $17.19M | $19.19M |
| Current assets | $63.08M | $73.27M |
| PP&E, net | $79.18M | $87.35M |
| Total assets | $142.63M | $160.72M |
| Current liabilities | $9.60M | $8.78M |
| Short-term debt | — | $332,480 |
| Long-term debt | $895,645 | $900,042 |
| Total debt | $895,645 | $1.23M |
| Total liabilities | $68.26M | $73.55M |
| Shareholders' equity | $74.38M | $87.17M |
| Net debt | -$1.69M | -$3.00M |
| Shares outstanding | 29.94M | 29.94M |
| Cash flow statement | ||
| Operating cash flow | -$7.06M | -$11.56M |
| Capital expenditure | — | $1.44M |
| Free cash flow | — | -$13.00M |
| Investing cash flow | $5.98M | $3.66M |
| Financing cash flow | -$567,321 | -$535,433 |
| Depreciation & amortization | $7.77M | $7.57M |
| Stock-based compensation | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.